✨ Free AI Report
HeartBeam, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research HeartBeam, Inc.
Company Research

HeartBeam, Inc.: Business Overview, Financials & Competitive Analysis

HeartBeam, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). Early-stage cardiac diagnostic innovator with transformative technology facing commercialization risks in a highly regulated medical device market. HeartBeam has achieved significant regulatory milestones (FDA clearances for arrhythmia and 12-lead ECG) and owns differentiated 3D ECG technology with strong patent protection. However, the company faces substantial execution risk as a pre-revenue.

What is HeartBeam, Inc.'s industry? HeartBeam, Inc. (heartbeam.com) operates in Medical Device Manufacturing - Cardiac Diagnostics. AskCyborg classifies HeartBeam, Inc. under Medical Device Manufacturing - Cardiac Diagnostics in its company registry.

HeartBeam is a medical technology company developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG. The platform is design...

5/ 10Mixed

Cyborg Score thesis

Early-stage cardiac diagnostic innovator with transformative technology facing commercialization risks in a highly regulated...

Read the full analyst-debate transcript →
Industry Medical Device Manufacturing - Cardiac Diagnostics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest HeartBeam, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for HeartBeam, Inc.

AskCyborg analysts argue the bull and bear cases for HeartBeam, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
HeartBeam, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

HeartBeam, Inc. Overview

Pro stress-test →

HeartBeam is a medical technology company developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG. The platform is designed for portable devices for patient use anywhere, enabling physicians to identify cardiac health trends outside traditional medical facilities.

Strategic Profile

Pro stress-test →

The company achieved FDA clearance for arrhythmia assessment in December 2024 and 12-lead ECG synthesis software in December 2025. HeartBeam ranked #2 worldwide in 12-lead ECG innovation among 243 companies analyzed, second only to GE HealthCare. The company holds over 20 issued patents related to technology enablement.

Competitive Landscape

Pro stress-test →

HeartBeam operates in the ambulatory electrocardiogram solutions market for cardiac disease detection. The company faces competition from established medtech players offering traditional ECG monitoring (GE HealthCare, Philips) and emerging digital health competitors in remote cardiac monitoring. HeartBeam's differentiation lies in its proprietary 3D ECG technology and ability to generate clinical-grade 12-lead output from cable-free portable devices.

Industry Context

HeartBeam, Inc. operates in Medical Device Manufacturing - Cardiac Diagnostics.

Key facts

Founded: 2015 · Headquarters: Santa Clara, California · Employees: 16-26 · Revenue: $750K · Market cap: $94.4M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on HeartBeam, Inc..

  • Cable-free 3D ECG device that synthesizes clinical-grade 12-lead ECG output for portable use
  • Recent FDA clearances for arrhythmia assessment (Dec 2024) and 12-lead synthesis (Dec 2025) de-risk regulatory pathway
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025FDA clearance for 12-lead ECG synthesis software
  • December 2024FDA clearance for arrhythmia assessment
  • +1 moreTrack every material event for HeartBeam, Inc. as it happens. Explore monitoring →
Get alerted when HeartBeam, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compare HeartBeam, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

HeartBeam, Inc. operates in Medical Device Manufacturing - Cardiac Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Device Manufacturing - Cardiac Diagnostics research →
NEW · MCP server

Ask your AI assistant about HeartBeam, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare HeartBeam, Inc. and its top competitor on Cyborg Score”
“What did HeartBeam, Inc. do this quarter?”
“Is HeartBeam, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does HeartBeam, Inc. do?+
HeartBeam is a medical technology company developing the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG. The platform is design...
What is HeartBeam, Inc.'s Cyborg Score?+
HeartBeam, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are HeartBeam, Inc.'s main competitors?+
Named competitors include Traditional 12-lead ECG Systems, Wearable Cardiac Monitoring, Remote Cardiac Monitoring. The full competitive landscape is in the AskCyborg report.
How can I get the full HeartBeam, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the HeartBeam, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track HeartBeam, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual